Navigation Links
JCI table of contents: Dec. 3, 2007
Date:12/3/2007

the origin of the fat cell

A recent study in the Journal of Clinical Investigation indicated that in mice, under certain circumstances (either a high-fat diet or treatment with the antidiabetic drug rosiglitazone), cells derived from the bone marrow known as BMDCPCs can act as precursors of fat cells (adipocytes). However, a new study in mice by Gou Young Koh and colleagues at the Korea Advanced Institute of Science and Technology, Republic of Korea, suggests that this is not the case. The potential reasons for these distinct observations, as well as the impact of the observation that BMDCPCs cannot become adipocytes in vivo, are discussed in an accompanying commentary by David Scadden from Massachusetts General Hospital Center for Regenerative Medicine, Boston.

In the study, mouse bone marrow cells expressing a fluorescent marker were transplanted into normal mice and the fat tissue of the recipient mice was analyzed for the presence or absence of marked cells 2 months later. No marked adipocytes were detected, even in mice fed a high-fat diet and in mice treated with rosiglitazone. Although marked cells that looked similar to adipocytes were observed in the fat tissues, further analysis indicated that these cells expressed no proteins characteristic of adipocytes. Instead, the marked cells expressed proteins characteristic of cells known as macrophages. The authors therefore concluded that BMDCPCs do not become adipocytes in vivo.

TITLE: Bone marrowderived circulating progenitor cells fail to transdifferentiate into adipocytes in adult adipose tissues in mice

AUTHOR CONTACT:
Gou Young Koh
Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Phone: 82-42-869-2638; Fax 82-42-869-2610; E-mail: gykoh@kaist.ac.kr.

View the PDF of this article at: https://www.the-jci.org/article.php?id=3
'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
4. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
5. Sheet of carbon atoms acts like a billiard table, physicists find
6. Sheet of carbon atoms acts like a billiard table, physicists find
7. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
9. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015 According to the new Market ... Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by ... , Asia-Pacific , Rest of the ... media market was valued at $247.7 million in 2014, which ... at a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/27/2015)... ... 27, 2015 , ... Visual Assay was named as a finalist for the ... technologies and services of the past year. More than 70 judges selected the finalists, ... will be announced at the 2015 R&D 100 Awards Dinner on November 13 at ...
(Date:7/24/2015)... (PRWEB) , ... July 24, 2015 , ... VetStem Biopharma, ... Center in support of stem cell therapy training and clinical opportunities. , “We are ... opportunity to veterinarians in the San Diego area. Stem cell therapy is an established ...
(Date:7/24/2015)... , July 24, 2015 Origin Agritech Limited (NASDAQ ... crop seeds in China , today announced ... fiscal year 2015 ended June 30, 2015, before the market ... will host a teleconference on August 5th, 2015, at 9:00 ... time to discuss the results. To participate in the call, ...
Breaking Biology Technology:Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3
... , KNOXVILLE, Tenn., Sept. 16 Marking ... colon cancer, EDP Biotech Corporation (EDP), ... today that its ColoMarker(TM) assay achieved 100 percent detection rate ... pre-clinical trials. ColoMarker is the first assay of its kind ...
... SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal steroid ... Stock Market on September 15, 2009. , , ... Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common ...
... Collaboration with Biomodels facilitates development of novel drug product , ... Inc., a biotechnology company developing oral antibodies for disease targets accessible ... a Phase I SBIR grant from the National Institute of Dental ... therapeutic for oral mucositis. , , Avaxia is ...
Cached Biology Technology:New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 2New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 3Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... personalized medicine for Parkinson,s disease, by investigating signs of ... cells respond to drug treatments. The study was funded ... collected skin cells from patients with genetically inherited forms ... They found that neurons derived from individuals with distinct ...
... is the way to go, if you are a primate ... orangutans, researchers have measured the energy required to navigate a ... up in the trees. Their work was presented at the ... July 2012. The findings help us to understand ...
... Laboratory of Neuro Imaging (LONI) has been responsible for ... generated by the Alzheimer,s Disease Neuroimaging Initiative (ADNI), an ... of Alzheimer,s disease. That stream of ... partners with an ambitious publicprivate effort to dig deeper ...
Cached Biology News:Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 2Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 3
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: